Pathological changes associated with AD can be ideally identified using the biological markers beta-amyloid (Aβ) and phosphorylated tau (Ptau) in CSF or positron emission tomography (PET), using radionuclide-labelled ligands that bind to these proteins [4,12]. This evidence concerns the gene MAPT and Alzheimer disease.